Investigating how to optimize radiation treatment for bladder cancer and head and neck cancer patients.
Molecular Characterization Trial
['FUNDING_OTHER'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10896481
This study is looking at how patients with muscle invasive bladder cancer and head and neck cancer respond to radiation therapy, especially when it's combined with new targeted treatments, to help improve their care and outcomes over time.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10896481 on ClinicalTrials.gov |
What this research studies
This research focuses on collecting and analyzing biological samples and data from patients with muscle invasive bladder cancer and head and neck squamous cell carcinoma. The goal is to understand how these patients respond to radiation therapy and to explore the potential benefits of combining radiation with new targeted anti-cancer treatments. By gathering information before, during, and after treatment, the study aims to uncover important insights that could improve patient outcomes. Patients will be involved in a longitudinal study that tracks their responses to various therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle invasive bladder cancer or head and neck squamous cell carcinoma who are scheduled to undergo radiation therapy.
Not a fit: Patients with non-invasive bladder cancer or other types of cancer not related to the study focus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation treatment strategies for cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in optimizing radiation therapy through biological insights, indicating that this approach could yield significant advancements.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MIAN, OMAR Y — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: MIAN, OMAR Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Bladder Cancer